You are here: Welcome » Jeremy Grimshaw

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision
Previous revision
Both sides next revision
jeremy_grimshaw [2022/05/09 08:17]
liam
jeremy_grimshaw [2022/05/09 08:23] (current)
liam [Antimicrobial Resistance]
Line 64: Line 64:
 Grimshaw received an operating grant from as a co-Principal Investigator from [[Diabetes Action Canada]] for a study called "An implementation Grimshaw received an operating grant from as a co-Principal Investigator from [[Diabetes Action Canada]] for a study called "An implementation
 science approach to increase attendance to retinopathy screening by people with [[diabetes]]."((Grimshaw, J. (2021). //Declaration of Interest.// Ontario COVID-19 Science Advisory Table. https://web.archive.org/web/20220508082748/https://covid19-sciencetable.ca/wp-content/uploads/2021/02/Declaration-of-Interest_Behavioural-Science-Working-Group_Jeremy-Grimshaw_20210513.pdf)) DAC is funded by [[pharmaceutical_companies:AstraZeneca]], [[pharmaceutical_companies:Bayer]], [[pharmaceutical_companies:Merck]] and [[Sun Life Financial]].((//Strategic Partners.// Diabetes Action Canada - SPOR Network. Retrieved May 8, 2022, from https://archive.ph/upCkV)) science approach to increase attendance to retinopathy screening by people with [[diabetes]]."((Grimshaw, J. (2021). //Declaration of Interest.// Ontario COVID-19 Science Advisory Table. https://web.archive.org/web/20220508082748/https://covid19-sciencetable.ca/wp-content/uploads/2021/02/Declaration-of-Interest_Behavioural-Science-Working-Group_Jeremy-Grimshaw_20210513.pdf)) DAC is funded by [[pharmaceutical_companies:AstraZeneca]], [[pharmaceutical_companies:Bayer]], [[pharmaceutical_companies:Merck]] and [[Sun Life Financial]].((//Strategic Partners.// Diabetes Action Canada - SPOR Network. Retrieved May 8, 2022, from https://archive.ph/upCkV))
 +
 +==== Antimicrobial Resistance ====
 +
 +Grimshaw has published research on [[antimicrobial resistance]] with funding by the [[Joint Programming Initiative on Antimicrobial Resistance Network]] (JPIARN).((Rzewuska, M., Charani, E., Clarkson, J. E., Davey, P. G., Duncan, E. M., Francis, J. J., Gillies, K., Kern, W. V., Lorencatto, F., Marwick, C. A., McEwen, J., Möhler, R., Morris, A. M., Ramsay, C. R., Rogers Van Katwyk, S., Skodvin, B., Smith, I., Suh, K. N., & Grimshaw, J. M. (2019). //Prioritizing research areas for antibiotic stewardship programmes in hospitals: a behavioural perspective consensus paper.// Clinical Microbiology and Infection, 25(2), 163–168. https://doi.org/10.1016/j.cmi.2018.08.020))
 ==== Awards and Recognition ==== ==== Awards and Recognition ====
  
 Grimshaw was recognized as a [[Thomson Reuters]] Highly Cited Researcher in 2015, 2016 2017 and 2018.((//ICES scientists Peter Austin and Jeremy Grimshaw selected as 2016 Thomson Reuters Highly Cited Researchers.// (2016, November 18). ICES. https://archive.ph/ieRPL)) ((Grimshaw, J. M. (2019, June 3). //Curriculum Vitae.// McMaster University Health Forum. https://web.archive.org/web/20220509011301/https://www.mcmasterforum.org/docs/default-source/people-cv/grimshaw-cv.pdf?sfvrsn=53d154d5_3)) Grimshaw was recognized as a [[Thomson Reuters]] Highly Cited Researcher in 2015, 2016 2017 and 2018.((//ICES scientists Peter Austin and Jeremy Grimshaw selected as 2016 Thomson Reuters Highly Cited Researchers.// (2016, November 18). ICES. https://archive.ph/ieRPL)) ((Grimshaw, J. M. (2019, June 3). //Curriculum Vitae.// McMaster University Health Forum. https://web.archive.org/web/20220509011301/https://www.mcmasterforum.org/docs/default-source/people-cv/grimshaw-cv.pdf?sfvrsn=53d154d5_3))
Back to top